ISTA allergy drug heading in the right direction
ISTA Pharmaceuticals has released promising preliminary results of a Phase II/III clinical study of its treatment for allergic conjunctivitis, bepotastine.
ISTA Pharmaceuticals has released promising preliminary results of a Phase II/III clinical study of its treatment for allergic conjunctivitis, bepotastine.
The study evaluated two concentrations, each dosed once and twice daily. Primary endpoints included efficacy in treating ocular itching and redness. Preliminary results demonstrate that both concentrations were highly statistically significant in the reduction of ocular itching, when dosed twice a day and in one concentration when dosed once a day. Both concentrations and dosing regimens also demonstrated highly statistically significant differences in the rapidity of response and the improvement in total nasal symptoms versus placebo. Evaluation of the second primary endpoint, ocular redness, showed a trend towards clinical significance but did not achieve statistical significance.
ISTA now plans to complete analysis of the data and discuss the results with the FDA to determine whether any further clinical studies are required before submitting a New Drug Application.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
